BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amo ...

Core Viewpoint - Haemonetics is positioned for growth due to the strong potential of its Plasma franchise and evolving hospital portfolio, despite facing economic uncertainties and foreign exchange challenges [1][11]. Financial Performance - The stock has increased by 11.7% over the past year, outperforming the industry, which fell by 1.3%, and the S&P 500, which rose by 26.7% [2]. - Haemonetics has a market capitalization of $4.84 billion and has consistently surpassed earnings estimates, achieving an average earnings surprise of 13.24% over the last four quarters [2]. Business Segments Plasma Franchise - The Plasma business unit focuses on collecting source plasma, with revenues growing by 6% in Q4 of fiscal 2024, driven by disposable volume and software [3]. - The collections environment in the U.S. remains favorable, with disposables growing by 4% in the quarter and 13% for fiscal 2024 [3]. - The rollout of the Express Plus technology has resulted in over 60,000 real-world collections, enhancing operational efficiency [3][4]. Hospital Business - Hospital revenues increased by 19% in Q4, supported by the success of Vascular Closure and hemostasis management [5]. - The Vascular Closure business is expanding due to new account openings in electrophysiology and interventional cardiology [5]. - The FDA's premarket approval for the VASSCADE MVPXL device and the ongoing international launch contributed approximately 300 basis points to revenue growth in Q4 [6]. Acquisitions and Innovations - In December 2023, Haemonetics acquired OpSens, enhancing its Hospital business with new technologies, generating nearly $10 million in revenues in Q4 [7]. - The launch of OptiWire and SavvyWire in April further supports the company's growth strategy [7]. Financial Stability - Haemonetics ended Q4 with cash and cash equivalents of $178.8 million and near-term payable debt of $10.2 million, indicating strong solvency [8]. - Long-term debt decreased to $797.6 million from $856.8 million in the previous quarter, with a total debt-to-capital ratio of 45.7%, down from 47.6% [10]. Challenges - Economic uncertainties, including inflation and rising interest rates, pose risks to Haemonetics' operations, leading to 700 basis points of margin pressure in Q4 [11]. - Foreign exchange fluctuations, particularly with the Japanese Yen and Euro, negatively impacted revenues due to international sales being conducted in local currencies [12]. Future Estimates - The Zacks Consensus Estimate for Haemonetics' fiscal 2025 earnings has increased to $4.46 from $4.24, with revenues projected at $1.40 billion, reflecting a 6.9% increase from the previous year [13].

BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Haemonetics also expects to grant the initial purchasers of the notes an option to purch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpor ...

Haemonetics (HAE) continues to expand its business, banking on growth drivers like Plasma, Thromboelastography (TEG), Hemostasis Management and the Vascular Closure business. The stock sports a Zacks Rank #1 (Strong Buy). The rollout of Persona — the company's proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections. Some other top-ranked stocks from the broader medical space are Medpace (MEDP) , ResMed (RMD) and Encompass ...

Its earnings are expected to grow 12% in the next five years. HAE's ROE for the trailing 12 months was 4.6%, better than the industry average of 0.2%. Will the Upside Continue? The Zacks Consensus Estimate for HAE's 2025 earnings is pegged at $1.40, indicating a 6.9% increase from the year-ago reported figure. The consensus estimate for 2025 revenues is pegged at $4.46 billion, indicating a year- over-year improvement of 12.6%. Haemonetics is gaining from the newly-completed limited market release of the ne ...

Shares of Haemonetics (HAE) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $97.35 in the previous session. Haemonetics has gained 12.5% since the start of the year compared to the 3.8% move for the Zacks Medical sector and the 2.9% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of 90 cents for the fourth quarter of fiscal 2024, up 16.9% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.3%.On a GAAP basis, EPS was 40 cents, down 29.8% from the prior-year quarter’s levels.For the full year, adjusted earnings were $3.96 per share, up 30.7% from the year-ago period’s figure. It beats the Zacks Consensus Estimate by 03%.Total RevenuesRevenues increased 12.8% to $343.3 million in the four ...

For the quarter ended March 2024, Haemonetics (HAE) reported revenue of $343.29 million, up 12.8% over the same period last year. EPS came in at $0.90, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $326.95 million, representing a surprise of +5.00%. The company delivered an EPS surprise of +2.27%, with the consensus EPS estimate being $0.88.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...